Table 2.
Clinical characteristics of the study group during follow up.
| Clinical Characteristics of the Study Group | STEMI Patients (n = 66) | NSTEMI Patients (n = 44) | p-Value |
|---|---|---|---|
| CCS class | 0.5 ± 0.8 | 0.6 ± 0.9 | p = 0.5 |
| NYHA class | 1.5 ± 0.95 | 1.6 ± 1.0 | p = 0.3 |
| EF (%) | 45.6 ± 9.9 | 49.5 ± 9.8 | p = 0.04 |
| Rehospitalization from cardiac causes | 41 p. (60.3%) | 27 p. (61.4%) | p = 0.9 |
| Rehospitalization from non-cardiac causes | 17 p. (25.0%) | 12 p. (27.3%) | p = 0.8 |
| Subsequent MI | 0 p. (0%) | 4 p. (9.1%) | p = 0.005 |
| Re-PCI | 18 p. (26.5%) | 10 p. (22.7%) | p = 0.6 |
| CABG | 10 p. (14.7%) | 5 p. (11.4%) | p = 0.6 |
| Stroke | 4 p. (5.9%) | 5 p. (11.4%) | p = 0.3 |
| Peripheral artery disease | 10 p. (14.7%) | 4 p. (9.1%) | p = 0.4 |
| Carotid artery disease | 2 p. (2.9%) | 2 p. (4.5%) | p = 0.6 |
| Smoking | 23 p. (33.8%) | 8 p. (18.2%) | p = 0.04 |
| Treatment | |||
| Aspirin | 58 p. (85.3%) | 38 p. (86.4%) | p = 0.9 |
| Clopidogrel | 8 p. (17.7%) | 8 p. (18.2%) | p = 0.3 |
| ACEIs | 47 p. (69.1%) | 23 p. (52.3%) | p = 0.04 |
| ARBs | 8 p. (11.8%) | 6 p. (13.6%) | p = 0.8 |
| Beta blockers | 63 p. (92.6%) | 39 p. (88.6%) | p = 0.5 |
| MRAs | 17 p. (25.0%) | 9 p. (20.5%) | p = 0.6 |
| Statins | 62 p. (91.2%) | 38 p. (86.4%) | p = 0.4 |
| Diuretics | 24 p. (35.3%) | 19 p. (43.2%) | p = 0.4 |
| Oral antidiabetic | 15 p. (22.1%) | 8 p. (18.2%) | p = 0.6 |
| Insulin | 6 p. (8.8%) | 4 p. (9.1%) | p = 0.9 |
| Oral anticoagulant | 6 p. (8.8%) | 3 p. (6.8%) | p = 0.5 |
ACEIs—angiotensin-converting enzyme inhibitors, ARBs—angiotensin II receptor antagonists, CABG—coronary artery bypass grafting, CCS—Canadian Cardiovascular Society, EF—ejection fraction, MI—myocardial infarction, MRAs—mineralocorticoid receptor antagonists, NSTEMI—non-ST-elevation myocardial infarction, NYHA—New York Heart Association, p.—patients, PCI—percutaneous coronary interventions, STEMI—ST-elevation myocardial infarction.